---
document_datetime: 2025-12-29 12:11:27
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/arsenic-trioxide-mylan.html
document_name: arsenic-trioxide-mylan.html
version: success
processing_time: 0.1242629
conversion_datetime: 2025-12-30 02:29:55.584615
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Arsenic trioxide Mylan

[RSS](/en/individual-human-medicine.xml/67281)

##### Withdrawn

This medicine's authorisation has been withdrawn

arsenic trioxide Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Arsenic trioxide Mylan](#news-on)
- [Related content](#related-content-1580)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 14 April 2025, the European Commission withdrew the marketing authorisation for Arsenic trioxide Mylan (arsenic trioxide) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Mylan Ireland Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Arsenic trioxide Mylan was granted marketing authorisation in the EU on 1 April 2020 for the treatment of acute promyelocytic leukaemia (APL) in adults with newly diagnosed low or intermediate risk APL, and in adults with APL whose disease did not respond to previous treatment with a retinoid and cancer medicines, or when the disease came back after this type of treatment.

The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2025.

Arsenic trioxide Mylan is a generic medicine of Trisenox. There are other generic medicinal products of Trisenox authorised and marketed in the EU.

Arsenic trioxide Mylan : EPAR - Medicine overview

Reference Number: EMA/64271/2020

English (EN) (250.08 KB - PDF)

**First published:** 17/04/2020

**Last updated:** 06/05/2025

[View](/en/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-121)

български (BG) (310.71 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/bg/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_bg.pdf)

español (ES) (250.86 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/es/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_es.pdf)

čeština (CS) (291.4 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/cs/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_cs.pdf)

dansk (DA) (241.54 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/da/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_da.pdf)

Deutsch (DE) (253.97 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/de/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_de.pdf)

eesti keel (ET) (228.76 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/et/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_et.pdf)

ελληνικά (EL) (316.29 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/el/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_el.pdf)

français (FR) (253.32 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/fr/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_fr.pdf)

hrvatski (HR) (277.48 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/hr/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_hr.pdf)

italiano (IT) (244.66 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/it/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (297.66 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/lv/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (285.37 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/lt/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_lt.pdf)

magyar (HU) (282.68 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/hu/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_hu.pdf)

Malti (MT) (299.42 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/mt/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_mt.pdf)

Nederlands (NL) (250.88 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/nl/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_nl.pdf)

polski (PL) (286.56 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/pl/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_pl.pdf)

português (PT) (253.37 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/pt/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_pt.pdf)

română (RO) (289.94 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/ro/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_ro.pdf)

slovenčina (SK) (284.19 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/sk/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_sk.pdf)

slovenščina (SL) (275.28 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/sl/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_sl.pdf)

Suomi (FI) (242.97 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/fi/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_fi.pdf)

svenska (SV) (243.73 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/sv/documents/overview/arsenic-trioxide-mylan-epar-medicine-overview_sv.pdf)

Arsenic trioxide Mylan : EPAR - Risk-management-plan summary

English (EN) (156.23 KB - PDF)

**First published:** 17/04/2020

**Last updated:** 06/05/2025

[View](/en/documents/rmp-summary/arsenic-trioxide-mylan-epar-risk-management-plan-summary_en.pdf)

## Product information

Arsenic trioxide Mylan : EPAR - Product information

English (EN) (1.56 MB - PDF)

**First published:** 17/04/2020

**Last updated:** 06/05/2025

[View](/en/documents/product-information/arsenic-trioxide-mylan-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-637)

български (BG) (2.35 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/bg/documents/product-information/arsenic-trioxide-mylan-epar-product-information_bg.pdf)

español (ES) (1.73 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/es/documents/product-information/arsenic-trioxide-mylan-epar-product-information_es.pdf)

čeština (CS) (1.96 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/cs/documents/product-information/arsenic-trioxide-mylan-epar-product-information_cs.pdf)

dansk (DA) (1.69 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/da/documents/product-information/arsenic-trioxide-mylan-epar-product-information_da.pdf)

Deutsch (DE) (1.87 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/de/documents/product-information/arsenic-trioxide-mylan-epar-product-information_de.pdf)

eesti keel (ET) (2.15 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/et/documents/product-information/arsenic-trioxide-mylan-epar-product-information_et.pdf)

ελληνικά (EL) (4.84 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/el/documents/product-information/arsenic-trioxide-mylan-epar-product-information_el.pdf)

français (FR) (1.79 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/fr/documents/product-information/arsenic-trioxide-mylan-epar-product-information_fr.pdf)

hrvatski (HR) (2.07 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/hr/documents/product-information/arsenic-trioxide-mylan-epar-product-information_hr.pdf)

íslenska (IS) (1.65 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/is/documents/product-information/arsenic-trioxide-mylan-epar-product-information_is.pdf)

italiano (IT) (1.68 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/it/documents/product-information/arsenic-trioxide-mylan-epar-product-information_it.pdf)

latviešu valoda (LV) (1.76 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/lv/documents/product-information/arsenic-trioxide-mylan-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.83 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/lt/documents/product-information/arsenic-trioxide-mylan-epar-product-information_lt.pdf)

magyar (HU) (1.97 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/hu/documents/product-information/arsenic-trioxide-mylan-epar-product-information_hu.pdf)

Malti (MT) (2.16 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/mt/documents/product-information/arsenic-trioxide-mylan-epar-product-information_mt.pdf)

Nederlands (NL) (1.62 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/nl/documents/product-information/arsenic-trioxide-mylan-epar-product-information_nl.pdf)

norsk (NO) (1.62 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/no/documents/product-information/arsenic-trioxide-mylan-epar-product-information_no.pdf)

polski (PL) (1.8 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/pl/documents/product-information/arsenic-trioxide-mylan-epar-product-information_pl.pdf)

português (PT) (1.69 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/pt/documents/product-information/arsenic-trioxide-mylan-epar-product-information_pt.pdf)

română (RO) (1.77 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/ro/documents/product-information/arsenic-trioxide-mylan-epar-product-information_ro.pdf)

slovenčina (SK) (1.97 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/sk/documents/product-information/arsenic-trioxide-mylan-epar-product-information_sk.pdf)

slovenščina (SL) (1.88 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/sl/documents/product-information/arsenic-trioxide-mylan-epar-product-information_sl.pdf)

Suomi (FI) (1.72 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/fi/documents/product-information/arsenic-trioxide-mylan-epar-product-information_fi.pdf)

svenska (SV) (1.65 MB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/sv/documents/product-information/arsenic-trioxide-mylan-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0013/G 14/01/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Arsenic trioxide Mylan : EPAR - All Authorised presentations

English (EN) (45.75 KB - PDF)

**First published:** 17/04/2020

**Last updated:** 06/05/2025

[View](/en/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-478)

български (BG) (99.15 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/bg/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_bg.pdf)

español (ES) (45.61 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/es/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (78.88 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/cs/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (44.76 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/da/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (54.1 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/de/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (45.66 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/et/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (84.41 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/el/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_el.pdf)

français (FR) (57.8 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/fr/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (75.69 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/hr/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (45.85 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/is/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (44.63 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/it/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (79.21 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/lv/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (75.83 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/lt/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (60.45 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/hu/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (80.18 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/mt/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (44.8 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/nl/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (44.89 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/no/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_no.pdf)

polski (PL) (81.44 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/pl/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_pl.pdf)

português (PT) (45.64 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/pt/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_pt.pdf)

română (RO) (76.11 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/ro/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (76.5 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/sk/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (59.56 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/sl/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (43.55 KB - PDF)

**First published:**

17/04/2020

**Last updated:**

06/05/2025

[View](/fi/documents/all-authorised-presentations/arsenic-trioxide-mylan-epar-all-authorised-presentations_fi.pdf)

## Product details

Name of medicine Arsenic trioxide Mylan Active substance arsenic trioxide International non-proprietary name (INN) or common name arsenic trioxide Therapeutic area (MeSH) Leukemia, Promyelocytic, Acute Anatomical therapeutic chemical (ATC) code L01XX27

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Arsenic trioxide Mylan is indicated for induction of remission, and consolidation in adult patients with:

The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.

## Authorisation details

EMA product number EMEA/H/C/005235

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Mylan Ireland Limited

Unit 35/36 Grange Parade Baldoye Industrial Estate Dublin 13 Ireland

Opinion adopted 30/01/2020 Marketing authorisation issued 01/04/2020 Withdrawal of marketing authorisation 14/04/2025 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Arsenic trioxide Mylan : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (311.14 KB - PDF)

**First published:** 25/05/2021

**Last updated:** 06/05/2025

[View](/en/documents/procedural-steps-after/arsenic-trioxide-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Arsenic trioxide Mylan : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/638190/2019

English (EN) (869.97 KB - PDF)

**First published:** 17/04/2020

**Last updated:** 06/05/2025

[View](/en/documents/assessment-report/arsenic-trioxide-mylan-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Arsenic trioxide Mylan

Adopted

Reference Number: EMA/CHMP/28370/2020

English (EN) (232.78 KB - PDF)

**First published:** 31/01/2020

**Last updated:** 06/05/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-arsenic-trioxide-mylan_en.pdf)

#### News on Arsenic trioxide Mylan

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2020) 31/01/2020

#### Related content

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-573)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

**This page was last updated on** 06/05/2025

## Share this page

[Back to top](#main-content)